Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis

Background Acral lentiginous melanoma is associated with worse survival than other subtypes of melanoma. Understanding prognostic factors for survival and recurrence can help better inform follow-up care. Objectives To analyze the clinicopathologic features, melanoma-specific survival, and recurrenc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Avani M. Kolla BPhil, Gerardo A. Vitiello MD, Erica B. Friedman MD, James Sun MD, Aishwarya Potdar MS, Hala Daou BS, Norma E. Farrow MD, Clara R. Farley MD, John T. Vetto MD, Dale Han MD, Marvi Tariq MD, Georgia M Beasley MD, Carlo M. Contreras MD, Michael Lowe MD, Jonathan S. Zager MD, Iman Osman MD, Russell S. Berman MD, Tracey N. Liebman MD, Jennifer A. Stein MD PhD, Ann Y. Lee MD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/57f410acb38d4768a497f22089e561a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57f410acb38d4768a497f22089e561a6
record_format	dspace
spelling	oai:doaj.org-article:57f410acb38d4768a497f22089e561a62021-11-09T23:03:52ZAcral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis1073-274810.1177/10732748211053567https://doaj.org/article/57f410acb38d4768a497f22089e561a62021-11-01T00:00:00Zhttps://doi.org/10.1177/10732748211053567https://doaj.org/toc/1073-2748Background Acral lentiginous melanoma is associated with worse survival than other subtypes of melanoma. Understanding prognostic factors for survival and recurrence can help better inform follow-up care. Objectives To analyze the clinicopathologic features, melanoma-specific survival, and recurrence-free survival by substage in a large, multi-institutional cohort of primary acral lentiginous melanoma patients. Methods Retrospective review of the United States Melanoma Consortium database, a multi-center prospectively collected database of acral lentiginous melanoma patients treated between January 2000 and December 2017. Results Of the 433 primary acral lentiginous melanoma patients identified (median [range] age: 66 [8–97] years; 53% female, 83% white), 66% presented with stage 0–2 disease and the median time of follow-up for the 392 patients included in the survival analysis was 32.5 months (range: 0–259). The 5-year melanoma-specific survivals by stage were 0 = 100%, I = 93.8%, II = 76.2%, III = 63.4%, IIIA = 80.8%, and IV = 0%. Thicker Breslow depth ((HR) = 1.13; 95% CI = 1.05–1.21; P < .001)) and positive nodal status ((HR) = 1.79; 95% CI = 1.00–3.22; P = .050)) were independent prognostic factors for melanoma-specific survival. Breslow depth ((HR = 1.13; 95% CI = 1.07–1.20; P < .001), and positive nodal status (HR = 2.12; 95% CI = 1.38–3.80; P = .001) were also prognostic factors for recurrence-free survival. Conclusion In this cohort of patients, acral lentiginous melanoma was associated with poor outcomes even in early stage disease, consistent with prior reports. Stage IIB and IIC disease were associated with particularly low melanoma-specific and recurrence-free survival. This suggests that studies investigating adjuvant therapies in stage II patients may be especially valuable in acral lentiginous melanoma patients.Avani M. Kolla BPhilGerardo A. Vitiello MDErica B. Friedman MDJames Sun MDAishwarya Potdar MSHala Daou BSNorma E. Farrow MDClara R. Farley MDJohn T. Vetto MDDale Han MDMarvi Tariq MDGeorgia M Beasley MDCarlo M. Contreras MDMichael Lowe MDJonathan S. Zager MDIman Osman MDRussell S. Berman MDTracey N. Liebman MDJennifer A. Stein MD PhDAnn Y. Lee MDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Control, Vol 28 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Avani M. Kolla BPhil Gerardo A. Vitiello MD Erica B. Friedman MD James Sun MD Aishwarya Potdar MS Hala Daou BS Norma E. Farrow MD Clara R. Farley MD John T. Vetto MD Dale Han MD Marvi Tariq MD Georgia M Beasley MD Carlo M. Contreras MD Michael Lowe MD Jonathan S. Zager MD Iman Osman MD Russell S. Berman MD Tracey N. Liebman MD Jennifer A. Stein MD PhD Ann Y. Lee MD Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis
description	Background Acral lentiginous melanoma is associated with worse survival than other subtypes of melanoma. Understanding prognostic factors for survival and recurrence can help better inform follow-up care. Objectives To analyze the clinicopathologic features, melanoma-specific survival, and recurrence-free survival by substage in a large, multi-institutional cohort of primary acral lentiginous melanoma patients. Methods Retrospective review of the United States Melanoma Consortium database, a multi-center prospectively collected database of acral lentiginous melanoma patients treated between January 2000 and December 2017. Results Of the 433 primary acral lentiginous melanoma patients identified (median [range] age: 66 [8–97] years; 53% female, 83% white), 66% presented with stage 0–2 disease and the median time of follow-up for the 392 patients included in the survival analysis was 32.5 months (range: 0–259). The 5-year melanoma-specific survivals by stage were 0 = 100%, I = 93.8%, II = 76.2%, III = 63.4%, IIIA = 80.8%, and IV = 0%. Thicker Breslow depth ((HR) = 1.13; 95% CI = 1.05–1.21; P < .001)) and positive nodal status ((HR) = 1.79; 95% CI = 1.00–3.22; P = .050)) were independent prognostic factors for melanoma-specific survival. Breslow depth ((HR = 1.13; 95% CI = 1.07–1.20; P < .001), and positive nodal status (HR = 2.12; 95% CI = 1.38–3.80; P = .001) were also prognostic factors for recurrence-free survival. Conclusion In this cohort of patients, acral lentiginous melanoma was associated with poor outcomes even in early stage disease, consistent with prior reports. Stage IIB and IIC disease were associated with particularly low melanoma-specific and recurrence-free survival. This suggests that studies investigating adjuvant therapies in stage II patients may be especially valuable in acral lentiginous melanoma patients.
format	article
author	Avani M. Kolla BPhil Gerardo A. Vitiello MD Erica B. Friedman MD James Sun MD Aishwarya Potdar MS Hala Daou BS Norma E. Farrow MD Clara R. Farley MD John T. Vetto MD Dale Han MD Marvi Tariq MD Georgia M Beasley MD Carlo M. Contreras MD Michael Lowe MD Jonathan S. Zager MD Iman Osman MD Russell S. Berman MD Tracey N. Liebman MD Jennifer A. Stein MD PhD Ann Y. Lee MD
author_facet	Avani M. Kolla BPhil Gerardo A. Vitiello MD Erica B. Friedman MD James Sun MD Aishwarya Potdar MS Hala Daou BS Norma E. Farrow MD Clara R. Farley MD John T. Vetto MD Dale Han MD Marvi Tariq MD Georgia M Beasley MD Carlo M. Contreras MD Michael Lowe MD Jonathan S. Zager MD Iman Osman MD Russell S. Berman MD Tracey N. Liebman MD Jennifer A. Stein MD PhD Ann Y. Lee MD
author_sort	Avani M. Kolla BPhil
title	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis
title_short	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis
title_full	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis
title_fullStr	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis
title_full_unstemmed	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis
title_sort	acral lentiginous melanoma: a united states multi-center substage survival analysis
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/57f410acb38d4768a497f22089e561a6
work_keys_str_mv	AT avanimkollabphil acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT gerardoavitiellomd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT ericabfriedmanmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT jamessunmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT aishwaryapotdarms acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT haladaoubs acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT normaefarrowmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT clararfarleymd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT johntvettomd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT dalehanmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT marvitariqmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT georgiambeasleymd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT carlomcontrerasmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT michaellowemd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT jonathanszagermd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT imanosmanmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT russellsbermanmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT traceynliebmanmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT jenniferasteinmdphd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT annyleemd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis
_version_	1718440745660055552

Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis

Ejemplares similares